ValuEngine upgraded shares of Waters (NYSE:WAT) from a hold rating to a buy rating in a research note released on Monday.
Other equities analysts have also recently issued reports about the company. Janney Montgomery Scott lifted their price target on Waters from $200.00 to $230.00 and gave the company a buy rating in a research report on Wednesday, January 24th. BTIG Research started coverage on Waters in a research note on Friday, January 5th. They set a buy rating and a $230.00 price objective for the company. Zacks Investment Research raised Waters from a hold rating to a buy rating and set a $217.00 price objective for the company in a research note on Tuesday, December 26th. Barclays raised their price objective on Waters from $202.00 to $208.00 and gave the stock an equal weight rating in a research note on Wednesday, January 24th. Finally, Morgan Stanley raised Waters from an underweight rating to an equal weight rating and set a $192.00 price objective for the company in a research note on Monday, December 4th. Twelve investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Waters has an average rating of Hold and a consensus target price of $205.13.
Waters stock opened at $211.18 on Monday. Waters has a 1 year low of $153.04 and a 1 year high of $220.20. The stock has a market capitalization of $16,779.51, a price-to-earnings ratio of 1,111.53, a PEG ratio of 2.55 and a beta of 0.91. The company has a debt-to-equity ratio of 0.85, a quick ratio of 6.60 and a current ratio of 7.04.
Waters (NYSE:WAT) last issued its quarterly earnings results on Tuesday, January 23rd. The medical instruments supplier reported $2.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.44 by $0.07. Waters had a return on equity of 24.70% and a net margin of 0.88%. The company had revenue of $687.28 million for the quarter, compared to analysts’ expectations of $671.98 million. During the same period last year, the firm earned $2.21 EPS. The firm’s revenue for the quarter was up 9.3% on a year-over-year basis. sell-side analysts predict that Waters will post 8.16 earnings per share for the current year.
In other news, SVP Mark T. Beaudouin sold 42,143 shares of the firm’s stock in a transaction on Thursday, January 25th. The stock was sold at an average price of $217.21, for a total value of $9,153,881.03. Following the completion of the sale, the senior vice president now owns 20,749 shares of the company’s stock, valued at $4,506,890.29. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Joann A. Reed sold 1,386 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $194.07, for a total value of $268,981.02. The disclosure for this sale can be found here. In the last ninety days, insiders sold 75,180 shares of company stock valued at $16,326,519. 5.07% of the stock is currently owned by insiders.
Several institutional investors have recently modified their holdings of WAT. Harding Loevner LP boosted its position in shares of Waters by 207.1% in the third quarter. Harding Loevner LP now owns 2,768,174 shares of the medical instruments supplier’s stock worth $158,275,000 after buying an additional 1,866,848 shares during the period. Renaissance Technologies LLC boosted its position in shares of Waters by 59.1% in the fourth quarter. Renaissance Technologies LLC now owns 1,429,049 shares of the medical instruments supplier’s stock worth $276,078,000 after buying an additional 530,949 shares during the period. Mackenzie Financial Corp boosted its position in shares of Waters by 157.5% in the third quarter. Mackenzie Financial Corp now owns 651,400 shares of the medical instruments supplier’s stock worth $116,939,000 after buying an additional 398,438 shares during the period. Deutsche Bank AG boosted its position in shares of Waters by 82.9% in the fourth quarter. Deutsche Bank AG now owns 351,977 shares of the medical instruments supplier’s stock worth $67,994,000 after buying an additional 159,576 shares during the period. Finally, Amundi Pioneer Asset Management Inc. boosted its position in shares of Waters by 359.9% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 157,768 shares of the medical instruments supplier’s stock worth $30,479,000 after buying an additional 123,464 shares during the period. 94.50% of the stock is owned by institutional investors and hedge funds.
Waters Company Profile
Waters Corporation is an analytical instrument manufacturer. The Company operates through two segments: Waters and TA. It designs, manufactures, sells and services high performance liquid chromatography (HPLC), ultra performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and post-warranty service plans.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.